Erik Springer
Impact in
- Microbiology top 5%
- Actinomycetales infections and treatment
- Oncology top 10%
- Bone health and treatments
Papers in
-
- Thyroid Cancer Diagnosis and Treatment 7
-
- Protease and Inhibitor Mechanisms 2
- Co-authors
- Helmut Erich Gabbert (3 shared papers)Csaba Mahotka (1 shared paper)Claus Dieter Gerharz (1 shared paper)Achim Weber (8 shared papers)Arno Schad (11 shared papers)C. James Kirkpatrick (6 shared papers)Thomas J. Musholt (6 shared papers)Torsten Hansen (2 shared papers)
- Journals
- Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin (3 papers)Oncotarget (1 paper)Langenbeck s Archives of Surgery (1 paper)Frontiers in Medicine (1 paper)Frontiers in Oncology (1 paper)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Erik Springer
29 papers receiving 1k citations
Peers
Comparison fields: 5 of 67
- Microbiology 28
- Oncology 220
- Endocrinology, Diabetes and Metabolism 160
- Molecular Biology 281
- Cell Biology 59
Countries citing papers authored by Erik Springer
This map shows the geographic impact of Erik Springer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Springer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Springer more than expected).
Fields of papers citing papers by Erik Springer
This network shows the impact of papers produced by Erik Springer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Springer. The network helps show where Erik Springer may publish in the future.
Co-authors
The 25 scholars most cited alongside Erik Springer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. | 1999 | 320 |
| 2 | 2007 | 164 | |
| 3 | 2001 | 93 | |
| 4 | 2010 | 63 | |
| 5 | 2019 | 61 | |
| 6 | 2006 | 57 | |
| 7 | 2017 | 36 | |
| 8 | 2010 | 29 | |
| 9 | 2018 | 27 | |
| 10 | 2014 | 23 | |
| 11 | 2006 | 20 | |
| 12 | 2010 | 20 | |
| 13 | 2016 | 19 | |
| 14 | 2018 | 17 | |
| 15 | 2007 | 16 | |
| 16 | 2015 | 16 | |
| 17 | 2006 | 14 | |
| 18 | 2019 | 13 | |
| 19 | 2010 | 11 | |
| 20 | 2023 | 9 |
About Erik Springer
Erik Springer is a scholar working on Endocrinology, Diabetes and Metabolism, Cancer Research, Oncology, Otorhinolaryngology and Genetics, having authored 29 papers that have together received 1.1k indexed citations. Recurring topics across this work include Thyroid Cancer Diagnosis and Treatment (7 papers), Protease and Inhibitor Mechanisms (2 papers), Microtubule and mitosis dynamics (2 papers), Renal Diseases and Glomerulopathies (2 papers), Neuroendocrine Tumor Research Advances (2 papers), Genetic factors in colorectal cancer (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and Head and Neck Cancer Studies (2 papers). The work is most often cited by research in Microbiology (28 citations), Oncology (220 citations), Endocrinology, Diabetes and Metabolism (160 citations), Molecular Biology (281 citations) and Cell Biology (59 citations). Erik Springer has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Helmut Erich Gabbert, Csaba Mahotka, Claus Dieter Gerharz, Achim Weber, Arno Schad, C. James Kirkpatrick, Thomas J. Musholt, Torsten Hansen, Martin Kunkel and Ekkehard Siegel. Their work appears in journals such as Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin, Oncotarget, Langenbeck s Archives of Surgery, Frontiers in Medicine and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.